Today, IMI is globally recognised as a pioneer of open innovation and an attractive model for successful PPPs in research. A true partnering machine, IMI forges collaborations that bring together stakeholders including universities, large pharmaceutical companies, SMEs, patient groups, and medicine regulators, as well as companies in other health-related sectors, such as diagnostics, imaging, and IT.
In this context IMI has decided to showcase IMI’s impact in specific areas, starting with three topics: diabetes, dementia and the relatively new field of data management. IMI will analyse the challenges and show how IMI-funded projects helped move the needle.
They are organising online live sessions where key actors representing each of the three areas will explore the key challenges and demonstrate how IMI contributed to progress in them. During these sessions, they will also share patients’ testimonies, as they are the ultimate beneficiaries of IMI’s funded research. Furthermore, they hope to engage IMI stakeholders in a broader discussion on IMI’s impact and ask them for their active participation in these live events.
Our project co-lead Gill Farrar will be presenting AMYPAD at the IMI impact event on dementia to be held on 15 June at 2:00-3:30 pm CET.
Registration for this event is free but obligatory. You can register and find out more about this event here.